Tofacitinib versus methotrexate as the first‐line disease‐modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open‐label randomized controlled trial

Abstract

As tofacitinib may be more effective than MTX according to previous reports such as the ORAL Start study, high-dose MTX (25 mg/week, subcutaneously) used in this study may be as efficacious as tofacitinib in patients with established RA who were DMARD naive or had not received a therapeutic dose of DMARDs. However, adverse effects differed between groups. Registered on: ClinicalTrials.gov; ID: NCT04464642.